Company: OSRH
Filing Date: 2025-05-20
Form Type: 10-Q
Source: 0001213900-25-045947
Chunk: 313

Company: OSR Holdings, Inc.
Filing Date: 2025-05-20
Form: 10-Q
Item: Part I, Item 8
Chunk 313
---
 market opportunity of DRT-101 relies on novel
Mechanism of Action of DRT-101 that can lead to potential first-in-class DMOAD (Disease-Modifying Osteoarthritis Drug) in the market.

Darnatein
is pursuing pre-clinical studies of DRT-101 targeting osteoarthritis and plans to file Investigational New Drug Application (IND) to
the U.S. Food and Drug Administration by 2025 for Phase 1 clinical trial, with aims of FDA approval by 2032. Darnatein will seek to create
cashflow via licensing deals from the preclinical and clinical developments of its pipeline assets.

Net
cashflow from the acquisitions for the three months ended March 31, 2025 and 2024 are as follows:

     2025 
  
    Net cash outflow arising from acquisition of Darnatein: 

    Cash consideration 
    $-  
  
    Less: cash and cash equivalent balances acquired 
     - 

    $         - 

     2024 
  
    Net cash outflow arising from acquisition of VAXIMM and RMC: 

    Cash consideration 
    $-  
  
    Less: cash and cash equivalent balances acquired 
     - 

    $         - 

(24)Commitment and contingencies

The
Group has no pending litigation cases arising in the ordinary course of business as of March 31, 2025 and December 31, 2024. The Parent
has entered into various contractual commitments related to the acquisition of VAXIMM including a future financial obligation of CHF
7,416 underlying as of March 31, 2025. Meanwhile, both parties have agreed to remove section 6.1.3 of the license agreement that states
that in the event of the Parent’s sale to a third party, the Licensor shall reimburse the Licensee for reasonable costs and expenses
incurred in the preparation, submission, maintenance, prosecution, and enforcement process.

(25)Segment reporting

The
Group operates in one operating segment. Operating segments are defined as components of an enterprise about which separate financial
information is evaluated regularly by the chief operating decision maker (“CODM”) in deciding how to allocate resources and
assessing performance. The Group’s CODM role is fulfilled by the Executive Leadership Team, who allocates resources and assesses
performance based upon consolidated financial information. The geographic segments